Oxford Immunotec Reports Third Quarter 2018 Financial Results
- Closed transformative deal to sell U.S. laboratory services business to Quest Diagnostics
- T-SPOT ® .TB tests sold in the third quarter exceeded one million tests for the first time
- Significant improvement in GAAP net loss; first quarter of positive non-GAAP adjusted EBITDA
OXFORD, United Kingdom and MARLBOROUGH, Mass., Nov. 09, 2018 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD), a global, high-growth diagnostics company, today announced third quarter 2018 financial results.
“We are very pleased with the continued strong growth in our TB business, as well as the Company’s continued progress on profitability metrics,” said Dr. Peter Wrighton-Smith, Chief Executive Officer of Oxford Immunotec. “The Quest transaction is a transformative event for the Company that well positions us for greater commercial and financial success”.
By revenue type, total revenues were, in millions:
|Three Months Ended September 30,|
By geography, total revenues were, in millions:
|Three Months Ended September 30,|
|Europe & ROW||2.3||2.2||3||%||4||%|
(a) Changes in revenue include the impact of changes in foreign currency exchange rates. We use the non-GAAP financial measure "constant currency basis" in our filings to show changes in our revenue without giving effect to period-to-period currency fluctuations. We consider the use of a period over period revenue comparison on a constant currency basis to be helpful to investors, as it provides a revenue growth measure free of positive or negative volatility due to currency fluctuations.
Third Quarter 2018 Financial Results
Revenue for the third quarter of 2018 was $16.1 million, representing a 7% increase from third quarter 2017 revenue of $15.0 million. On a constant currency basis, revenue growth was 8% versus the prior year period.
2018 third quarter product revenue was $15.1 million, representing a 12% increase from product revenue of $13.4 million in the third quarter of 2017. Service revenue for the third quarter of 2018 was $1.0 million, down 40% from 2017 third quarter service revenue of $1.6 million. The decrease in service revenue was driven by an expected decline in blood donor screening revenue.
United States revenue was $2.9 million in the third quarter of 2018, representing a 15% decline from revenue of $3.4 million in the prior year period. Growth in our core tuberculosis business was offset by an expected decline in blood donor screening revenue.
Europe & ROW revenue was $2.3 million in the third quarter of 2018, representing a 3% increase compared to the third quarter of 2017. On a constant currency basis, Europe & ROW revenue increased 4% versus the third quarter of 2017.
Asia revenue was $10.9 million in the third quarter of 2018, representing an increase of 16% compared to 2017 third quarter revenue of $9.4 million. On a constant currency basis, Asia revenue increased 18% versus the third quarter of 2017.
Gross profit for the third quarter of 2018 was $11.5 million, an increase of approximately $1.7 million from gross profit of $9.8 million in the same period of 2017. Gross margin was 71.5%, an increase of 650 basis points from gross margin of 65.0% in the third quarter of 2017.
Operating expenses were $16.5 million in the third quarter of 2018, a decrease of approximately $11.1 million compared to $27.6 million in the third quarter of 2017. Excluding one-time items, operating expenses for the third quarter of 2018 decreased approximately $900k compared to the third quarter of 2017.
Net loss for the third quarter of 2018 was $3.5 million, or $0.13 per share, compared to $16.8 million, or $0.70 per share, in the third quarter of 2017. Net loss per share was based on 26,033,550 and 24,123,574 weighted average ordinary shares outstanding for the third quarters of 2018 and 2017, respectively.
EBITDA for the third quarter of 2018 was $(1.2) million compared to $(14.7) million in the third quarter of 2017. Adjusted EBITDA was $2.3 million for the third quarter of 2018 compared to $(2.5) million in the same period in 2017. Both EBITDA and Adjusted EBITDA are non-GAAP measures.
Quest Diagnostics Completes Acquisition of Our U.S. Laboratory Services Business
On November 6, 2018, Quest Diagnostics completed its previously announced acquisition of our U.S. laboratory services business. The T-SPOT.TB tuberculosis and the Accutix tick-borne disease testing services are now part of Quest Diagnostics’ portfolio of innovative infectious disease testing services. As part of the transaction, we will sell T-SPOT.TB test kits and related accessories to Quest Diagnostics under the terms of a long-term supply agreement. In addition, the parties have entered into a strategic collaboration agreement to drive continued growth of T-SPOT.TB testing in the U.S.
The transaction represents a strategic business shift having a major effect on our operations and financial results. Accordingly, the assets and liabilities of this business have been classified as held for sale and the related operations reported in discontinued operations in our condensed consolidated financial statements for all periods presented.
Supplemental Financial Information
To assist investors in understanding third quarter results excluding the disposition of the U.S. laboratory services business, Oxford Immunotec has provided Unaudited Non-GAAP Pro Forma Condensed Combined Statement of Operations for the quarterly period ended September 30, 2018 as Exhibit 99.2 to our Current Report on Form 8-K furnished on November 9, 2018.
Oxford Immunotec will host a conference call on Friday, November 9, 2018 at 8:00 a.m. Eastern Time to discuss its third quarter 2018 financial results. The call will be concurrently webcast. To listen to the conference call on your telephone, please dial (855) 363-5047 for United States callers and +1 (484) 365-2897 for international callers and reference confirmation code 7673307 approximately ten minutes prior to start time. To access the live audio webcast or subsequent archived recording, visit the Investor Relations section of Oxford Immunotec's website at www.oxfordimmunotec.com. The replay will be available on the Company's website for approximately 60 days.
About Oxford Immunotec
Oxford Immunotec Global PLC is a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions. The Company's T-SPOT.TB test has been approved for sale in over 50 countries, including the United States, where it has received pre-market approval from the Food and Drug Administration, Europe, where it has obtained a CE mark, as well as Japan and China. The Company is headquartered near Oxford, U.K. and in Marlborough, MA. Additional information can be found at www.oxfordimmunotec.com.
T-SPOT and the Oxford Immunotec logo are trademarks of Oxford Immunotec Ltd.
This release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this release are forward-looking statements. This includes statements about Oxford Immunotec's anticipated plans, objectives, intentions, the anticipated benefits of the transaction, the effects of the transaction, including effects on future financial and operating results, prospects for sales of its products and other statements that are not historical facts. Actual events or results may differ materially from those described in this release due to a number of risks and uncertainties. Risks and uncertainties include, among others: the potential disruption of management time from ongoing business operations due to the transaction; the risk that Oxford Immunotec may fail to realize the expected benefits from the transaction; the risk that the announcement of the completion of the transaction could have adverse effects on the market price of Oxford Immunotec's ordinary shares; decisions by regulatory authorities, hospitals and other health care institutions, laboratories, physicians, patients and third party payers that could affect Oxford Immunotec's business and prospects; Oxford Immunotec’s exposure to potential litigation and contingent liabilities pursuant to the transaction; as well as Oxford Immunotec’s ability to expeditiously and successfully expand its sales and distribution networks. The risks included above are not exhaustive. Other factors that could adversely affect Oxford Immunotec's business and prospects are described under the "Risk Factors" section in its filings with the Securities and Exchange Commission ("SEC"). Oxford Immunotec's SEC filings are available for free by visiting the investor section of its website, www.oxfordimmunotec.com, or the SEC's website, www.sec.gov.
Investors should give careful consideration to these risks and uncertainties. Forward-looking statements contained herein are based on current expectations and assumptions and currently available data and are neither predictions nor guarantees of future events or performance. You should not place undue reliance on forward-looking statements contained herein, which speak only as of the date of this release. Oxford Immunotec does not undertake to update or revise any forward-looking statements after they are made, whether as a result of new information, future events, or otherwise, except as required by applicable law.
For Media and Investor Inquiries:
VP, Strategy and Investor Relations
Tel: +1 (508) 556-1377
|Oxford Immunotec Global PLC|
|Condensed consolidated statements of operations|
Three months ended
Nine months ended
|(in thousands, except share and per share data)||2018||2017||2018||2017|
|Cost of revenue:|
|Total cost of revenue||4,573||5,247||12,870||14,832|
|Research and development||1,754||2,931||5,969||8,092|
|Sales and marketing||6,432||7,257||20,655||22,175|
|General and administrative||8,132||7,066||19,349||19,456|
|Change in fair value of contingent purchase price consideration||—||(880||)||—||(3,475||)|
|Intangible assets impairment charge||—||11,064||—||11,064|
|Total operating expenses||16,530||27,634||47,952||67,143|
|Operating loss from continuing operations||(5,053||)||(17,870||)||(16,436||)||(39,851||)|
|Interest expense, net||(673||)||(781||)||(2,011||)||(2,411||)|
|Foreign exchange losses||(52||)||(624||)||(306||)||(1,277||)|
|Other income (expense)||5||—||(242||)||(262||)|
|Loss from continuing operations before income taxes||(5,773||)||(19,275||)||(18,995||)||(43,801||)|
|Income tax expense from continuing operations||(485||)||(222||)||(1,182||)||2,189|
|Loss from continuing operations||(6,258||)||(19,497||)||(20,177||)||(41,612||)|
|Income (loss) from discontinued operations before income taxes||2,774||2,650||(104||)||(73||)|
|Income tax expense||—||—||—||—|
|Income (loss) from discontinued operations||2,774||2,650||(104||)||(73||)|
|Net loss from continuing operations per ordinary share—basic and diluted||$||(0.24||)||$||(0.81||)||$||(0.78||)||$||(1.80||)|
|Net income (loss) from discontinued operations per ordinary share—basic and diluted||0.11||0.11||0.00||0.00|
|Net loss per ordinary share—basic and diluted||$||(0.13||)||$||(0.70||)||$||(0.78||)||$||(1.80||)|
|Oxford Immunotec Global PLC|
|Reconciliation of net loss to Adjusted EBITDA (a)|
|Three months ended September 30,||Nine months ended September 30,|
|Income tax expense (benefit)||486||222||1,183||(2,189||)|
|Interest expense, net.||534||641||1,590||1,982|
|Depreciation and amortization of intangible assets||1,167||1,122||3,410||3,115|
|Accretion and amortization of loan fees||140||140||421||429|
|Share-based compensation expense||1,016||1,506||3,763||4,266|
|Unrealized exchange (gains) losses||(234||)||333||(717||)||614|
|Change in fair value of contingent purchase price consideration||—||(880||)||—||(3,475||)|
|Intangible assets impairment charges||—||11,064||—||11,064|
(a) EBITDA and Adjusted EBITDA are non-GAAP measures that we calculate as net loss, adjusted for the impact of earnings or charges resulting from matters that we consider not to be indicative of our ongoing operations. We believe that these measures provide useful information to investors in understanding and evaluating our operating results in the same manner as our management and Board of Directors. Our presentation of these measures is not made in accordance with U.S. GAAP, and our computation of these measures may vary from others in the industry. Our use of these measures has limitations as an analytical tool, and you should not consider it in isolation or as a substitute for analysis of our results as reported under U.S. GAAP.
The above table presents a reconciliation of net loss, the most comparable U.S. GAAP measure, to EBITDA and Adjusted EBITDA for each of the periods indicated.
|Oxford Immunotec Global PLC|
|Condensed consolidated balance sheets|
|September 30,||December 31,|
|(in thousands, except share and per share data)||2018||2017|
|Cash and cash equivalents||$||70,156||$||90,332|
|Accounts receivable, net||7,080||6,021|
|Prepaid expenses and other assets||2,957||2,711|
|Current assets held for sale||31,899||14,281|
|Total current assets||118,206||120,482|
|Restricted cash, non-current||200||200|
|Property and equipment, net||6,428||2,764|
|Other intangible assets, net||958||1,036|
|Deferred tax asset||885||2,486|
|Noncurrent assets held for sale||—||14,785|
|Liabilities and shareholders’ equity|
|Current portion of loans payable||30,200||78|
|Current liabilities held for sale||4,361||4,630|
|Total current liabilities||52,996||22,445|
|Long-term portion of loans payable||97||29,856|
|Noncurrent liabilities held for sale||37||48|
|Ordinary shares, £0.006705 nominal value; 36,183,293 shares authorized at
September 30, 2018 and December 31, 2017, and 26,337,963 and
25,661,634 shares issued and outstanding at September 30, 2018 and
December 31, 2017, respectively
|Additional paid-in capital||300,802||294,613|
|Accumulated other comprehensive loss||(7,290||)||(5,712||)|
|Total shareholders’ equity||71,966||87,629|
|Total liabilities and shareholders’ equity||$||129,160||$||144,236|
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg saker fra GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra GlobeNewswire
First Quarter 2019 Results Conference Call24.4.2019 19:55:00 CEST | Pressemelding
AURORA, Ontario, April 24, 2019 (GLOBE NEWSWIRE) -- Magna International Inc. (TSX: MG ) (NYSE: MGA ) FIRST QUARTER 2019 RESULTS CONFERENCE CALL THURSDAY – MAY 9, 2019 8:30 AM ET DIAL IN NUMBERS North America: 1-800-954-0587 International: 1-312-281-2942 Webcast: www.magna.com Slide presentation will be available on our website prior to the call. REBROADCAST INFORMATION Replay available 2 hours after the call until May 16, 2019 North America: 1-800-558-5253 International: 1-416-626-4100 Reservation No.: 21922562 INVESTOR CONTACT Louis Tonelli, Vice-President, Investor Relations email@example.com 905-726-7035 TELECONFERENCE CONTACT Nancy Hansford, Executive Assistant, Investor Relations firstname.lastname@example.org 905-726-7108
Flashpoint Strengthens Intelligence Platform with New Dashboards and Analytics, Expanded Collections and Tailored Alerting by Industry24.4.2019 16:00:00 CEST | Pressemelding
Company Significantly Expands Use-Case Driven Business Risk Intelligence (BRI) Offerings NEW YORK, April 24, 2019 (GLOBE NEWSWIRE) -- Flashpoint, the global leader in Business Risk Intelligence (BRI), today announced new innovations and enhancements that help multiple teams bolster cybersecurity, confront fraud, detect insider threats, enhance corporate and physical security, and address third-party risk. The new innovations and enhancements strengthen Flashpoint Intelligence Platform, which grants access to the company’s archive of finished intelligence reports, data from illicit forums, marketplaces, chat services, paste sites, technical data, card and account shops, and vulnerabilities, in a finished intelligence experience. The platform scales Flashpoint’s internal team of specialized, multilingual intelligence analysts’ ability to quickly provide responses to customers. “As a long-time Flashpoint customer, I have seen many iterations of the company’s platform, technology, and coll
VSBLTY LAUNCHES NEW CORPORATE WEBSITE;SHOWCASES MARKETING & SECURITY TECHNOLOGY24.4.2019 14:05:00 CEST | Pressemelding
Philadelphia, PA, April 24, 2019 (GLOBE NEWSWIRE) -- VSBLTY Groupe Technologies Corp. (CSE: VSBY) (Frankfurt: 5VS) is pleased to announce the launch of its new, upgraded website (vsblty.net) that demonstrates “The Intersection of Marketing & Security.” VSBLTY is a leading software technology company that provides consumer audience measurement using the power of machine learning through computer vision. Its industry-leading VisionCaptor™ and DataCaptor™ combines motion graphics or interactive brand messaging on any digital display at point of customer contact with “first of its kind” FacialAnalytics. VSBLTY’s measurement technology records demographics such as age, gender, and sentiment as well as audience measurement including content touches, traffic counts, and dwell time. Jay Hutton, VSBLTY Co-Founder and CEO, said, “Our website shows how our digital display solutions are transforming public spaces and providing actionable marketing insights. In addition, VSBLTY Vector™, our disrupt
Fiverr Adds Depth to Management Team, Announces Hila Klein as Chief Operating Officer24.4.2019 14:00:00 CEST | Pressemelding
The veteran executive brings over 15 years of leadership experience to the company as it continues to build upon its mission of changing how the world works together NEW YORK, April 24, 2019 (GLOBE NEWSWIRE) -- Fiverr, a marketplace that connects businesses with freelancers offering digital services, is proud to announce the appointment of Hila Klein as Chief Operating Officer. Klein has a strong background as a product and technology executive, having most recently served as a Senior Vice President, Head of Product Technologies Division at 888 Holdings. She will report directly to Fiverr CEO, Micha Kaufman. “Over the past year, Fiverr has grown both as a business and as an organization. That means the stakes are higher and the challenges are bigger,” said Micha Kaufman, Fiverr CEO. “As such, it was necessary for us to bring in someone to help us oversee all internal processes and procedures. Hila has demonstrated the leadership capabilities that are necessary to help us improve our cr
Qtum Launches Enterprise Blockchain Solution — Unita24.4.2019 10:00:00 CEST | Pressemelding
SHANGHAI, China, April 24, 2019 (GLOBE NEWSWIRE) -- Qtum, the open-source public blockchain platform, launched Unita, a blockchain protocol designed for enterprises. Unita securely stores data, utilizes existing developer tools and automates information transfer processes for businesses at a groundbreaking speed of 10,000 transactions per second. Unita’s flexibility allows a wide population of developers to use common tools to solve the biggest problems businesses face when considering adopting blockchain technology, including consumer data regulations and verification. Unita takes advantage of an innovative, unique, and scalable consensus algorithm, SCAR, that allows parameter adjustments to take place on the blockchain. The dynamic nature of SCAR saves substantial amounts of disk space, bandwidth, and other network resources. Miguel Palencia, Chief Information Officer of the Qtum Foundation, said: “Speed and customization are two of the main barriers for enterprises looking to adopt
Percona Names Martin James Vice President of Sales EMEA & APAC24.4.2019 09:00:00 CEST | Pressemelding
James Brings Over 25 Years of Sales Management Experience to Percona RALEIGH, N.C., April 24, 2019 (GLOBE NEWSWIRE) -- Percona , a leader in open source database software and services, has named Martin James vice president of sales for the EMEA and APAC regions. With more than 25 years of experience building and leading sales teams in Europe, James will be responsible for the entire Percona EMEA sales operation, including direct sales, business development and partner channels. Percona is a leader in providing best-of-breed, enterprise-class support, consulting, managed services, training and software for MySQL, MariaDB, MongoDB, PostgreSQL and other open source databases in on-premises and cloud environments. An unbiased, trusted partner, Percona provides single-source expertise in multi-vendor environments that eliminates lock-in, increases agility and enables business growth. Prior to joining Percona, James was the regional vice president of Northern Europe for open source database